Chris Bates

Chris Bates
T: +44 (0) 20 7246 0523
E: chris.bates@alantra.com

Chris is a Vice President with eight years’ experience in M&A and transaction services.

He works alongside our Partners and Directors to deliver all types of deals including company acquisitions and disposals, management buy-outs (MBOs), fund raisings and strategic reviews, acting for business owners, management teams, corporates and private equity.

Recent deals include the sale of Vivona Brands and International Dance Supplies, the management buy-out of TTC Group, and advising ConSol Partners on an investment in the business by Empresaria. Chris is also a member of our Consumer sector team.

Chris graduated from Nottingham University with a First Class Honours Degree in Politics and American Studies. He qualified as a chartered accountant at PwC where he was a senior associate in Transaction Services. He is also an Ambassador for the Prince’s Trust and Young Enterprise.

Outside of work Chris is an avid reader, a keen rugby player, football supporter and is a season ticket holder at Chelsea FC.

 

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.